UB5-22535-67254
3 vaccinations
1 coded response
3 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 900 / CA
- Registered
- 2022-01-01
- Relationship
- Self
- Race
- Other
- Ethnicity
- Hispanic or Latino
Timeline
-
2021-02-09
Dose 1 — Pfizer-BioNTech
-
2021-03-02
Dose 2 — Pfizer-BioNTech
-
2021-12-31
Dose 3 — Pfizer-BioNTech
-
2022-01-01
Registered in v-safe
-
2022-01-02
Survey response — days 1–6 daily, dose 3MedDRA: Cough, Dyspnoea — Feeling: Poor · Fever · Headache, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: cough, shortness of breathMedDRA releases: 2024-11 · check-in free text available
- 2022-01-16
- 2022-02-13
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-09 | Pfizer-BioNTech | No |
| 2 | 2021-03-02 | Pfizer-BioNTech | No |
| 3 | 2021-12-31 | Pfizer-BioNTech | No |
Free text
Release 10 — days 1–6 daily, dose 3
Systemic reaction (other): cough, shortness of breath
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SRO | Cough | · | · | ✓ |
| SRO | Dyspnoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release